Nuclear medicine practice in Japan: A report of the sixth nationwide survey in 2007

Yasuo Kuwabara, Kiyoshi Koizumi, Yo Ushijima, Seigo Kinuya, Shigeo Kinomura, Kazuyoshi Suga, Hiroko Takeoka, Tohru Takeda, Hiroshi Toyama, Yasuo Arao, Yoshihiro Nishiyama, Kouji Murakami, Koichi Morita

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective: The Subcommittee on the Survey of Nuclear Medicine Practice in Japan has performed a nationwide survey of nuclear medicine practice every 5 years since 1982 to provide detailed information on its present status. Methods: Questionnaires were sent to all institutions known to the Japan Radioisotope Association to conduct nuclear medicine examinations. The questionnaires addressed the number and kind of nuclear medicine examinations performed as well as the kind and dose of the radiopharmaceuticals used during the month of June 2007. The annual number of total or specific examinations was then estimated. Results: Of the institutions sent questionnaires, 1219 were for in vivo study, 49 for in vitro study, and 212 for positron emission tomography (PET) study. Of these, 92.2% provided answers. A total of 1569 gamma cameras were installed in 1119 institutions, of which 70% were dual-head cameras. The estimated total annual number of in vivo examinations expressed by the number of administered radiopharmaceuticals was 1.41 million, representing a decrease of 11.5% when compared with that of the previous survey (2002). The frequency of study with respect to single-photon emission computed tomography (SPECT) slightly increased to 42.3% from 39.9% in the previous survey. The most frequently performed scintigraphy was bone (38.3%), followed by myocardium (26.2%) and brain perfusion (14.1%). Brain perfusion scintigraphy slightly increased, whereas tumor scintigraphy decreased by one-half when compared with the previous survey. The most commonly used radiopharmaceutical for each scintigraphy was 99m Tc-HMDP for bone, thallium-201 ( 201 Tl)-chloride for myocardium, gallium-67 ( 67 Ga)-citrate for tumor, and technetium-99m-ethylcysteinate dimmer ( 99m Tc-ECD) for brain. The number of PET institutes increased from 36 to 212. 18 F- fluorodeoxyglucose ( 18 F-FDG)-PET dramatically increased 14.8-fold during the past 5 years. Radionuclide therapy also increased. 131 I therapy for thyroid cancer and hyperthyroidism was conducted yearly in 2373 and 4146 patients, respectively. A total of 13.1 million in vitro radioassays were carried out yearly, the number of which has been decreasing continuously since 1992. Conclusions: It was proved that the content of nuclear medicine practice in Japan has changed considerably in the past 5 years. Namely, 18 F-FDG-PET and radionuclide therapy increased. This report might be useful for understanding the present trends of nuclear medicine practice in Japan.

Original languageEnglish
Pages (from-to)209-215
Number of pages7
JournalAnnals of Nuclear Medicine
Volume23
Issue number2
DOIs
Publication statusPublished - 01-02-2009

Fingerprint

Nuclear Medicine
Japan
Positron-Emission Tomography
Radiopharmaceuticals
Radioisotopes
Radionuclide Imaging
Fluorodeoxyglucose F18
Myocardium
Brain
Bone and Bones
Gamma Cameras
Perfusion Imaging
Surveys and Questionnaires
Thallium
Technetium
Hyperthyroidism
Single-Photon Emission-Computed Tomography
Thyroid Neoplasms
Neoplasms
Therapeutics

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

Cite this

Kuwabara, Y., Koizumi, K., Ushijima, Y., Kinuya, S., Kinomura, S., Suga, K., ... Morita, K. (2009). Nuclear medicine practice in Japan: A report of the sixth nationwide survey in 2007. Annals of Nuclear Medicine, 23(2), 209-215. https://doi.org/10.1007/s12149-008-0214-4
Kuwabara, Yasuo ; Koizumi, Kiyoshi ; Ushijima, Yo ; Kinuya, Seigo ; Kinomura, Shigeo ; Suga, Kazuyoshi ; Takeoka, Hiroko ; Takeda, Tohru ; Toyama, Hiroshi ; Arao, Yasuo ; Nishiyama, Yoshihiro ; Murakami, Kouji ; Morita, Koichi. / Nuclear medicine practice in Japan : A report of the sixth nationwide survey in 2007. In: Annals of Nuclear Medicine. 2009 ; Vol. 23, No. 2. pp. 209-215.
@article{eddec341e31b471f9516746484adf615,
title = "Nuclear medicine practice in Japan: A report of the sixth nationwide survey in 2007",
abstract = "Objective: The Subcommittee on the Survey of Nuclear Medicine Practice in Japan has performed a nationwide survey of nuclear medicine practice every 5 years since 1982 to provide detailed information on its present status. Methods: Questionnaires were sent to all institutions known to the Japan Radioisotope Association to conduct nuclear medicine examinations. The questionnaires addressed the number and kind of nuclear medicine examinations performed as well as the kind and dose of the radiopharmaceuticals used during the month of June 2007. The annual number of total or specific examinations was then estimated. Results: Of the institutions sent questionnaires, 1219 were for in vivo study, 49 for in vitro study, and 212 for positron emission tomography (PET) study. Of these, 92.2{\%} provided answers. A total of 1569 gamma cameras were installed in 1119 institutions, of which 70{\%} were dual-head cameras. The estimated total annual number of in vivo examinations expressed by the number of administered radiopharmaceuticals was 1.41 million, representing a decrease of 11.5{\%} when compared with that of the previous survey (2002). The frequency of study with respect to single-photon emission computed tomography (SPECT) slightly increased to 42.3{\%} from 39.9{\%} in the previous survey. The most frequently performed scintigraphy was bone (38.3{\%}), followed by myocardium (26.2{\%}) and brain perfusion (14.1{\%}). Brain perfusion scintigraphy slightly increased, whereas tumor scintigraphy decreased by one-half when compared with the previous survey. The most commonly used radiopharmaceutical for each scintigraphy was 99m Tc-HMDP for bone, thallium-201 ( 201 Tl)-chloride for myocardium, gallium-67 ( 67 Ga)-citrate for tumor, and technetium-99m-ethylcysteinate dimmer ( 99m Tc-ECD) for brain. The number of PET institutes increased from 36 to 212. 18 F- fluorodeoxyglucose ( 18 F-FDG)-PET dramatically increased 14.8-fold during the past 5 years. Radionuclide therapy also increased. 131 I therapy for thyroid cancer and hyperthyroidism was conducted yearly in 2373 and 4146 patients, respectively. A total of 13.1 million in vitro radioassays were carried out yearly, the number of which has been decreasing continuously since 1992. Conclusions: It was proved that the content of nuclear medicine practice in Japan has changed considerably in the past 5 years. Namely, 18 F-FDG-PET and radionuclide therapy increased. This report might be useful for understanding the present trends of nuclear medicine practice in Japan.",
author = "Yasuo Kuwabara and Kiyoshi Koizumi and Yo Ushijima and Seigo Kinuya and Shigeo Kinomura and Kazuyoshi Suga and Hiroko Takeoka and Tohru Takeda and Hiroshi Toyama and Yasuo Arao and Yoshihiro Nishiyama and Kouji Murakami and Koichi Morita",
year = "2009",
month = "2",
day = "1",
doi = "10.1007/s12149-008-0214-4",
language = "English",
volume = "23",
pages = "209--215",
journal = "Annals of Nuclear Medicine",
issn = "0914-7187",
publisher = "Springer Japan",
number = "2",

}

Kuwabara, Y, Koizumi, K, Ushijima, Y, Kinuya, S, Kinomura, S, Suga, K, Takeoka, H, Takeda, T, Toyama, H, Arao, Y, Nishiyama, Y, Murakami, K & Morita, K 2009, 'Nuclear medicine practice in Japan: A report of the sixth nationwide survey in 2007', Annals of Nuclear Medicine, vol. 23, no. 2, pp. 209-215. https://doi.org/10.1007/s12149-008-0214-4

Nuclear medicine practice in Japan : A report of the sixth nationwide survey in 2007. / Kuwabara, Yasuo; Koizumi, Kiyoshi; Ushijima, Yo; Kinuya, Seigo; Kinomura, Shigeo; Suga, Kazuyoshi; Takeoka, Hiroko; Takeda, Tohru; Toyama, Hiroshi; Arao, Yasuo; Nishiyama, Yoshihiro; Murakami, Kouji; Morita, Koichi.

In: Annals of Nuclear Medicine, Vol. 23, No. 2, 01.02.2009, p. 209-215.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Nuclear medicine practice in Japan

T2 - A report of the sixth nationwide survey in 2007

AU - Kuwabara, Yasuo

AU - Koizumi, Kiyoshi

AU - Ushijima, Yo

AU - Kinuya, Seigo

AU - Kinomura, Shigeo

AU - Suga, Kazuyoshi

AU - Takeoka, Hiroko

AU - Takeda, Tohru

AU - Toyama, Hiroshi

AU - Arao, Yasuo

AU - Nishiyama, Yoshihiro

AU - Murakami, Kouji

AU - Morita, Koichi

PY - 2009/2/1

Y1 - 2009/2/1

N2 - Objective: The Subcommittee on the Survey of Nuclear Medicine Practice in Japan has performed a nationwide survey of nuclear medicine practice every 5 years since 1982 to provide detailed information on its present status. Methods: Questionnaires were sent to all institutions known to the Japan Radioisotope Association to conduct nuclear medicine examinations. The questionnaires addressed the number and kind of nuclear medicine examinations performed as well as the kind and dose of the radiopharmaceuticals used during the month of June 2007. The annual number of total or specific examinations was then estimated. Results: Of the institutions sent questionnaires, 1219 were for in vivo study, 49 for in vitro study, and 212 for positron emission tomography (PET) study. Of these, 92.2% provided answers. A total of 1569 gamma cameras were installed in 1119 institutions, of which 70% were dual-head cameras. The estimated total annual number of in vivo examinations expressed by the number of administered radiopharmaceuticals was 1.41 million, representing a decrease of 11.5% when compared with that of the previous survey (2002). The frequency of study with respect to single-photon emission computed tomography (SPECT) slightly increased to 42.3% from 39.9% in the previous survey. The most frequently performed scintigraphy was bone (38.3%), followed by myocardium (26.2%) and brain perfusion (14.1%). Brain perfusion scintigraphy slightly increased, whereas tumor scintigraphy decreased by one-half when compared with the previous survey. The most commonly used radiopharmaceutical for each scintigraphy was 99m Tc-HMDP for bone, thallium-201 ( 201 Tl)-chloride for myocardium, gallium-67 ( 67 Ga)-citrate for tumor, and technetium-99m-ethylcysteinate dimmer ( 99m Tc-ECD) for brain. The number of PET institutes increased from 36 to 212. 18 F- fluorodeoxyglucose ( 18 F-FDG)-PET dramatically increased 14.8-fold during the past 5 years. Radionuclide therapy also increased. 131 I therapy for thyroid cancer and hyperthyroidism was conducted yearly in 2373 and 4146 patients, respectively. A total of 13.1 million in vitro radioassays were carried out yearly, the number of which has been decreasing continuously since 1992. Conclusions: It was proved that the content of nuclear medicine practice in Japan has changed considerably in the past 5 years. Namely, 18 F-FDG-PET and radionuclide therapy increased. This report might be useful for understanding the present trends of nuclear medicine practice in Japan.

AB - Objective: The Subcommittee on the Survey of Nuclear Medicine Practice in Japan has performed a nationwide survey of nuclear medicine practice every 5 years since 1982 to provide detailed information on its present status. Methods: Questionnaires were sent to all institutions known to the Japan Radioisotope Association to conduct nuclear medicine examinations. The questionnaires addressed the number and kind of nuclear medicine examinations performed as well as the kind and dose of the radiopharmaceuticals used during the month of June 2007. The annual number of total or specific examinations was then estimated. Results: Of the institutions sent questionnaires, 1219 were for in vivo study, 49 for in vitro study, and 212 for positron emission tomography (PET) study. Of these, 92.2% provided answers. A total of 1569 gamma cameras were installed in 1119 institutions, of which 70% were dual-head cameras. The estimated total annual number of in vivo examinations expressed by the number of administered radiopharmaceuticals was 1.41 million, representing a decrease of 11.5% when compared with that of the previous survey (2002). The frequency of study with respect to single-photon emission computed tomography (SPECT) slightly increased to 42.3% from 39.9% in the previous survey. The most frequently performed scintigraphy was bone (38.3%), followed by myocardium (26.2%) and brain perfusion (14.1%). Brain perfusion scintigraphy slightly increased, whereas tumor scintigraphy decreased by one-half when compared with the previous survey. The most commonly used radiopharmaceutical for each scintigraphy was 99m Tc-HMDP for bone, thallium-201 ( 201 Tl)-chloride for myocardium, gallium-67 ( 67 Ga)-citrate for tumor, and technetium-99m-ethylcysteinate dimmer ( 99m Tc-ECD) for brain. The number of PET institutes increased from 36 to 212. 18 F- fluorodeoxyglucose ( 18 F-FDG)-PET dramatically increased 14.8-fold during the past 5 years. Radionuclide therapy also increased. 131 I therapy for thyroid cancer and hyperthyroidism was conducted yearly in 2373 and 4146 patients, respectively. A total of 13.1 million in vitro radioassays were carried out yearly, the number of which has been decreasing continuously since 1992. Conclusions: It was proved that the content of nuclear medicine practice in Japan has changed considerably in the past 5 years. Namely, 18 F-FDG-PET and radionuclide therapy increased. This report might be useful for understanding the present trends of nuclear medicine practice in Japan.

UR - http://www.scopus.com/inward/record.url?scp=65349097952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65349097952&partnerID=8YFLogxK

U2 - 10.1007/s12149-008-0214-4

DO - 10.1007/s12149-008-0214-4

M3 - Article

C2 - 19225946

AN - SCOPUS:65349097952

VL - 23

SP - 209

EP - 215

JO - Annals of Nuclear Medicine

JF - Annals of Nuclear Medicine

SN - 0914-7187

IS - 2

ER -

Kuwabara Y, Koizumi K, Ushijima Y, Kinuya S, Kinomura S, Suga K et al. Nuclear medicine practice in Japan: A report of the sixth nationwide survey in 2007. Annals of Nuclear Medicine. 2009 Feb 1;23(2):209-215. https://doi.org/10.1007/s12149-008-0214-4